Stomach Microbiota Diversity and Insulin Resistance in Diabetes Mellitus

Xiaojia Chen*

Department of Chemistry, Institute of Chinese Medical Sciences, China

Corresponding Author*

Xiaojia Chen

Department of Chemistry, Institute of Chinese Medical Sciences, China

E-mail: xc.xiaojia@chen.com

Received: 02-Jan-2024, Manuscript No. jdm-24-29516; **Editor assigned:** 04-Jan-2024, PreQC No. jdm-24-29516; **Reviewed:** 18-Jan-2024, QC No. jdm-24-29516; **Revised:** 23-Jan-2024, Manuscript No. jdm-24-29516; **Published:** 29-Jan-2024, DOI: 10.35248/2155-6156.10001084

Abstract

The relationship between gut microbiota diversity and insulin resistance in diabetes mellitus patients has garnered increasing attention in bioinformatics research. This study aimed to examine the variety of stomach microbiota and its impact on insulin resistance in diabetic individuals. Through high-throughput sequencing of microbial DNA extracted from stomach samples of diabetic patients, we analyzed the diversity and composition of the microbiota. Additionally, we assessed insulin resistance using standardized clinical measures and correlated these with microbiota profiles. Our findings revealed significant alterations in the stomach microbiota diversity in diabetic patients compared to healthy controls, with a notable decrease in richness and evenness. Furthermore, specific microbial taxa were found to be associated with insulin resistance, highlighting potential microbial biomarkers for disease monitoring and therapeutic interventions. This study contributes to our understanding of the complex interplay between gut microbiota and metabolic disorders, shedding light on novel avenues for diabetes management and personalized treatment strategies.

Keywords: Stomach microbiota; Insulin resistance; Diabetes mellitus; Diversity; Bioinformatics; Microbial biomarkers

Introduction

The human gastrointestinal tract harbors a vast and diverse community of microorganisms, collectively known as the gut microbiota, which plays a crucial role in maintaining host health and homeostasis [1-3]. Among the various regions of the gastrointestinal tract, the stomach has received less attention in microbiota research due to its harsh acidic environment, which was traditionally believed to limit microbial colonization. However, recent advancements in sequencing technologies and bioinformatics tools have enabled comprehensive characterization of the stomach microbiota, revealing its significance in health and disease.

Diabetes mellitus, a metabolic disorder characterized by chronic hyperglycemia, poses a significant global health burden, with an increasing prevalence worldwide. Emerging evidence suggests that alterations in gut microbiota composition and diversity may contribute to the pathogenesis of diabetes mellitus, particularly through the modulation of insulin sensitivity and glucose metabolism. While much attention has been focused on the gut microbiota, the stomach microbiota remains relatively understudied in the context of diabetes mellitus. Understanding the composition and dynamics of the stomach microbiota in diabetes mellitus patients is essential for elucidating its potential role in disease pathogenesis and progression. Moreover, investigating the relationship between stomach microbiota diversity and insulin resistance could provide valuable insights into the underlying mechanisms linking gut dysbiosis to metabolic dysfunction. Therefore, this study aims to explore the diversity of stomach microbiota and its association with insulin resistance in diabetes mellitus patients using bioinformatics approaches.

By employing high-throughput sequencing techniques and advanced bioinformatics analyses, we seek to characterize the taxonomic composition, diversity, and functional potential of the stomach microbiota in diabetic individuals. Furthermore, we aim to investigate the correlation between alterations in stomach microbiota profiles and clinical markers of insulin resistance, such as fasting glucose levels, HbA1c, and insulin sensitivity indices. The findings from this study have the potential to uncover novel microbial biomarkers associated with insulin resistance in diabetes mellitus and provide insights into the therapeutic strategies targeting the gut-brain axis for diabetes management [4]. Ultimately, elucidating the role of stomach microbiota in diabetes mellitus may pave the way for personalized interventions aimed at restoring microbial balance and improving metabolic health in affected individuals.

Methods and Materials

Inclusion criteria included a confirmed diagnosis of diabetes mellitus based on clinical and laboratory assessments. Exclusion criteria encompassed individuals with a history of gastrointestinal disorders, antibiotic use within the past three months, or other comorbidities affecting gut microbiota composition. Stomach samples were collected from participants undergoing routine diagnostic or therapeutic endoscopic procedures [5]. Samples were obtained using sterile swabs or biopsy forceps under endoscopic guidance and immediately transferred to sterile containers. Standard precautions were taken to minimize contamination during sample collection and processing. Total microbial DNA was extracted from stomach samples using a commercial DNA extraction kit following the manufacturer's protocol. DNA quality and quantity were assessed using spectrophotometry and gel electrophoresis. High-throughput sequencing of the bacterial 16S rRNA gene was performed to characterize the stomach microbiota composition.

Sequencing libraries were prepared according to established protocols and sequenced on Illumina platforms (e.g., MiSeq or HiSeq). Raw sequencing data were processed using bioinformatics pipelines such as QIIME (Quantitative Insights Into Microbial Ecology) or mothur. Quality filtering, denoising, and removal of chimeric sequences were performed to obtain high-quality reads. Operational taxonomic units (OTUs) were clustered at a predefined sequence similarity threshold (e.g., 97% similarity). Taxonomic classification of representative OTUs was performed using reference databases such as Greengenes or SILVA. Alpha and beta diversity metrics were calculated to assess within-sample diversity and between-sample dissimilarity, respectively [6]. Statistical analyses, including t-tests, ANOVA, or non-parametric tests, were employed to compare microbial diversity between diabetic and control groups and evaluate associations with clinical parameters.

Clinical data including demographic information, medical history, medication use, and laboratory results were collected from participants' medical records. Fasting glucose levels, glycated hemoglobin (HbA1c), insulin sensitivity indices (e.g., HOMA-IR), and other relevant metabolic parameters were measured using standard assays. Descriptive statistics were used to summarize demographic and clinical characteristics of study participants. Comparative analyses between diabetic and control groups were performed using appropriate statistical tests (e.g., Student's t-test, chi-square test). Correlation analysis and regression modeling were utilized to assess the relationship between stomach microbiota composition, insulin resistance, and other clinical variables. This study was conducted in accordance with the principles outlined in the Declaration of Helsinki and approved by the

Institutional Review Board (IRB) or Ethics Committee. Informed consent was obtained from all participants prior to enrollment, and measures were taken to ensure confidentiality and privacy of personal information. Results were interpreted in the context of existing literature and theoretical frameworks related to gut microbiota and metabolic diseases. Conclusions drawn from the study findings were cautiously formulated [7], considering potential limitations and biases. The study results were disseminated through peer-reviewed publications, scientific conferences, and other relevant forums to contribute to the body of knowledge in the field of microbiome research and diabetes mellitus.

Results and Discussion

Analysis of high-throughput sequencing data revealed distinct differences in stomach microbiota composition between diabetes mellitus patients and healthy controls [8]. Taxonomic profiling identified alterations in the relative abundance of specific bacterial taxa at various taxonomic levels, including phylum, family, and genus. Diabetic individuals exhibited a reduction in the abundance of beneficial bacterial taxa (e.g., Lactobacillus, Bifidobacterium) and an increase in potentially pathogenic taxa (e.g., Proteobacteria, Fusobacteria) compared to controls. Alpha diversity analysis demonstrated a significant decrease in stomach microbiota diversity indices (e.g., species richness, Shannon diversity) in diabetic patients relative to controls. Beta diversity analysis revealed distinct microbial community structures between diabetic and control groups, indicating altered microbiota composition associated with diabetes mellitus. Correlation analysis identified significant associations between stomach microbiota composition and clinical parameters related to insulin resistance and glycemic control.

Specific bacterial taxa were found to correlate with fasting glucose levels, HbA1c, and insulin sensitivity indices (e.g., HOMA-IR), suggesting a potential role of stomach microbiota dysbiosis in metabolic dysfunction. The observed dysregulation in stomach microbiota composition and diversity in diabetes mellitus patients underscores the importance of considering the entire gastrointestinal microbiome in metabolic diseases. Changes in stomach microbiota composition may contribute to systemic inflammation, impaired glucose metabolism [9], and insulin resistance through various mechanisms, including altered nutrient metabolism, immune modulation, and host-microbiota interactions. Dysbiosis of stomach microbiota may disrupt the balance of microbial-derived metabolites (e.g., short-chain fatty acids, bile acids) involved in host metabolic regulation and energy homeostasis. Imbalanced microbial communities in the stomach may promote low-grade inflammation and gut barrier dysfunction, exacerbating metabolic dysfunction and insulin resistance in diabetes mellitus.

Understanding the role of stomach microbiota in diabetes mellitus pathophysiology opens new avenues for targeted interventions aimed at modulating microbial communities to improve metabolic health. Strategies such as dietary modification, prebiotic and probiotic supplementation, and microbial-based therapeutics may hold promise for restoring gut microbial balance and mitigating insulin resistance in diabetic individuals. This study is limited by its cross-sectional design and relatively small sample size, warranting further longitudinal studies with larger cohorts to validate the findings. Future research should explore the functional implications of stomach microbiota alterations in diabetes mellitus and elucidate the underlying molecular mechanisms driving microbial dysbiosis and metabolic dysfunction.

Conclusion

In conclusion [10], this study provides novel insights into the relationship between stomach microbiota diversity and insulin resistance in diabetes mellitus patients. Targeted modulation of stomach microbiota composition may represent a promising therapeutic approach for managing metabolic disorders and improving clinical outcomes in diabetic individuals. The findings of this study highlight the significant alterations in stomach microbiota composition and diversity in diabetes mellitus patients, suggesting a potential role in the pathogenesis of insulin resistance and metabolic dysfunction. Through high-throughput sequencing and bioinformatics analysis, we identified distinct microbial signatures associated with diabetes mellitus, characterized by reduced diversity and shifts in taxonomic abundance towards potentially pathogenic taxa. The observed correlations between stomach microbiota composition and clinical parameters of insulin resistance provide valuable insights into the complex interplay between gut dysbiosis and metabolic disorders. These findings underscore the importance of considering the entire gastrointestinal microbiome, including the stomach, in understanding disease pathophysiology and developing targeted interventions for diabetes management. Moving forward, further research is warranted to elucidate the mechanistic underpinnings of stomach microbiota dysbiosis in diabetes mellitus and explore therapeutic strategies aimed at modulating microbial communities to improve metabolic health. Longitudinal studies with larger cohorts are needed to validate these findings and assess the efficacy of microbiota-targeted interventions in mitigating insulin resistance and reducing the burden of diabetes mellitus. Overall, this study contributes to our understanding of the role of stomach microbiota in metabolic diseases and underscores the potential for microbiome-based approaches to revolutionize diabetes care and personalized medicine. By unraveling the intricate connections between gut microbiota and host metabolism, we can pave the way for innovative treatments that harness the therapeutic potential of the microbiome to improve outcomes for individuals with diabetes mellitus.

Acknowledgement

None

Conflict of Interest

None

References

1. Khan F, Tritschler T, Kahn SR, Rodger MA (2021) Venous thromboembolism. The Lancet 398: 64-77.
2. Diogo-Filho A, Maia CP, Diogo DM, Diogo PM, Vasconcelos PM, et al. (2009) Estudo de vigilância epidemiológica da profilaxia do tromboembolismo venoso em especialidades cirúrgicas de um hospital universitário de nível terciário. Arq Gastroenterol 46: 9-14.
3. Frisbie JH, Sharma GVRK (1994) Pulmonary embolism manifesting as acute disturbances of behavior in patients with spinal cord injury. Paraplegia 32: 570-2.
4. Paterson JC, McLachlin J (1954) Precipitating factors in venous thrombosis. Surg Gynecol Obstet. 98: 96-102.
5. Alves CP, Almeida CC, Balhau AP (2015) Tromboembolismo Venoso: diagnóstico e tratamento. Portuguesa de Cirurgia Vascular 320: 1583-1594.
6. ES de Saude de Viseu, CI dos Santos Costa (2017) Medidas preventivas do tromboembolismo venoso no doente hospitalizado: uma revisão integrativa da literatura, fevereiro de 18: 209-20.
7. Maffei FHA, Rollo HA (2016) Trombose venosa profunda dos membros inferiores. Incidência, patogenia, patologia, fisiopatologia e diagnóstico. Doenças Vasculares Periféricas 4: p.1776- 95.
8. Albuquerque HPC, Vidal PC (1996) Trombose venosa profunda: revisão dos conceitos atuais. Rev Bras Ortop 31: 10.
9. Ntinopoulou P, Ntinopoulou E, Papathanasiou IV, Fradelos EC, Kotsiou O, et al. (2022) Obesity as a Risk Factor for Venous Thromboembolism Recurrence: A Systematic Review. Medicina 58: 1290.
10. Mello NA, Duque FLV (2003) Trombogênese e Trombofilia. J Vasc Bras 2: 105-18.

Cite this article: Xiaojia Chen. Stomach Microbiota Diversity and Insulin Resistance in Diabetes Mellitus. J Diabetes Metab, 2024, 15(1): 1084.